Stanford inventors have developed an information theoretic, seizure detection algorithm for electroencephalography (EEG) towards improving diagnosis, management, and treatment of patients with epilepsy.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.
Stanford researchers have made a genetic mouse model to mimic the human LOXHD1 p.R1090Q mutation as a means to further investigate, understand and combat human Age-Related Hearing Loss (ARHL).
Researchers in the Burns group at Stanford designed a reaction methodology that allows for a green and inexpensive cycloaddition of amine or amide-containing unactivated olefins for the synthesis of biologically relevant cyclobutanes.
Researchers at Stanford, Yale, Rutgers, and the Karolinska Institute (Sweden) have developed a rapid and cheap method to detect genetic material from pathogenic infections (viral, bacterial, etc.) using electrical impedance measurement of amplified DNA nanoballs.
Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.
Researchers in Prof. Mark Kay's laboratory have developed variant AAV (adeno-associated virus) vectors with specificity and high transduction efficiency for pancreatic alpha- and beta- islet cells.
Stanford researchers have invented a method and developed compositions of matter to reduce the production of infectious viruses in cells that line the respiratory tract. The invention enables the use of gene-silencing approaches to prevent and treat viral infections.
A major barrier in CAR-T cell therapies has been T cell exhaustion, which affects the durability and effectiveness of treatments, particularly for solid tumors.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.